Analysts at B. Riley decreased their FY2025 EPS estimates for shares of Bicycle Therapeutics in a research note issued to ...

Investment analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Bicycle Therapeutics in a research note ...

Bicycle Therapeutics ( NASDAQ:BCYC ) Full Year 2024 Results Key Financial Results Revenue: US$35.3m (up 31% from FY... CAMBRIDGE, England & BOSTON, February 25, 2025--Bicycle Therapeutics plc ...

In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other small–cap stocks insiders are selling recently. Why are some investors focusing ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Jefferies lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $42 from $53 and keeps a Buy rating on the shares. For the FY24 ...

UK biotech Bicycle Therapeutics has raised £40 million ($52m) in a new funding round to help it progress its pipeline, including its lead compound, a first-in-class cancer treatment. The company ...

Bicycle Therapeutics is currently conducting the Phase 2/3 Duravelo-2 registrational trial evaluating zelenectide pevedotin plus pembrolizumab versus chemotherapy in first-line mUC (Cohort 1), and ...

In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top performing European stocks. As per Deloitte, inflation in the Eurozone ...